Mixed Earnings But Strong Sales For US Companies
Sales by US pharmaceutical companies were strong in the last fiscal reporting period ended December 1995. Some, such as biotechnology firms, are loss-making as they continue to invest in product development.
Amgen had a successful year in both financial and R&D terms. The firm's two key products, Epogen (epoetin alfa) and Neupogen (filgrastim), "continue to generate good financial results for investors, while funding a large aggressive R&D program," commented Gordon Binder, chairman and chief executive. Worldwide sales of Neupogen were up 12% in the fourth quarter of 1995 to $246 million. For the year, Neupogen sales grew 13% to $936 million. Epogen sales in the fourth quarter were $238 million, up 23%, and up 22% for the year to $721 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze